GlaxoSmithKline is continuing its makeover in the executive team that runs its R&D group.
The olmutinib development program is finally dead. South Korea’s Hanmi has determined that the drug — once partnered with Boehringer Ingelheim and Zai Lab — is no longer commercially viable. The drug was seen as more or less equivalent to AstraZeneca’s Tagrisso, according to Hanmi. So they’ve opted to punt the late-stage trial and shelve it once and for all.
South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.